* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Memory Pharmaceuticals

Memory Pharma realigns operations

pharmiweb.co.uk
Mar 20, 2008 3 related
        

Montvale, New Jersey Memory Pharmaceuticals Corp. announced that it has realigned its operations, reallocated resources and extended the preclinical research portion of its PDE10 collaboration with Amgen. The company will focus its near-term and mid- term efforts on two...

add comment

Memory Pharmaceuticals to change focus, cut jobs

marketwatch.com
Mar 12, 2008 15 related
        

LONDON (MarketWatch) -- Memory Pharmaceuticals said it's going to focus on two partnered programs, its nicotinic alpha-7 receptor agonist collaboration with Roche and the PDE10 collaboration with Amgen , and two proprietary programs, its PDE4 inhibitor and 5-HT6 antagonist programs, and will...

add comment

Memory Pharmaceuticals' MEM 1003 Fails in Bipolar Mania Trial

pharmiweb.co.uk
Mar 9, 2008
        

Genetic Engineering News ... reported top-line data from the Phase IIa study of MEM 1003 in acute mania in bipolar disorder. An analysis of the primary and secondary outcome measures in the trial indicated that MEM 1003 did not prove effective for the treatment of bipolar...

add comment

NI Research Releases Publications on Spinal Cord Injury and Alzheimer's (Marketwire)

yahoo.com
Mar 9, 2008
        

NI Research today announced the release of two publications: ... 1) The December issue of NeuroInvestment reviews and evaluates therapeutics-under-development for the treatment of spinal cord injury. While neurorehabilitative and neurosurgical techniques have become more...

add comment

Schizophrenia: Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in...

newsrx.com
Mar 9, 2008 2 related
        

Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The biomarker study,...

add comment

NASDAQNEWS: Memory Pharmaceuticals Corp. Reports the Fourth Quarter and Year end Results

pharmiweb.co.uk
Mar 7, 2008 3 related
        

Macro World Investor ... Released : Friday, March 07, 2008 4:59 AM InvestorIM has been created as a tool for the average investor. On March 6, 2008 Memory Pharmaceuticals Corp. (Nasdaq: MEMY), a biopharmaceutical company focused on the discovery and development of...

add comment

MG Strategies: Has added Memory Pharmaceuticals Corp. to their watch list

pharmiweb.co.uk
Mar 7, 2008 1 related
        

Stockhouse Canada ... Mar 07, 2008 (M2 PRESSWIRE via COMTEX News Network) -- Visit www.maybachfinancial.com for a complimentary subscription to the Maybach service and receive at no cost our "Special Report#1: Protecting Our Future" plus a second free report "Special...

add comment

Memory Pharmaceuticals Corp posts figures for fourth quarter and full year 2007

m2.com
Mar 7, 2008 206 related
        

Memory Pharmaceuticals Corp (Nasdaq: MEMY), a biopharmaceutical company focused on the discovery and development of drug candidates, announced on 6 March its financial results for the fourth quarter and year ended 31 December 2007. ... The company announced a net loss of...

add comment

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results (PR Newswire)

yahoo.com
Mar 6, 2008 242 related
        

Memory Pharmaceuticals Corp. , a biopharmaceutical company focused on the discovery and development of innovative drug candidates for the treatment of a broad range of central nervous system conditions, today reported its financial results for the fourth quarter and year ended December 31, 2007.

add comment

Memory Pharma Q4 Loss Narrows; Revenue Declines [MEMY]

pharmiweb.co.uk
Mar 6, 2008 37 related
        

RTTNews.com ... 3/6/2008 12:08:54 PM Memory Pharmaceuticals Corp. (MEMY), a biopharmaceutical company based in Montvale, New Jersey, on Thursday reported a narrower net loss for the fourth quarter, while revenues declined from the year-ago period. The net loss for the...

add comment